Nr1d1 Regulates Microglia M1/M2 Polarization to Alleviate Neuroinflammation after Traumatic Brain Injury

Mei Li1,2, Xianhao Huo2, Xu Zhao3

  • 1Department of Neurosurgery, First Medical Center, Chinese PLA General Hospital, Beijing 100853, PR China.

ACS Chemical Neuroscience
|November 26, 2025
PubMed

Insights

Activating Nr1d1 (nuclear receptor subfamily 1, group D, member 1) helps traumatic brain injury (TBI) recovery by reducing neuroinflammation and improving neurological function. This study highlights Nr1d1 as a potential therapeutic target for TBI treatment.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Microglia-driven neuroinflammation is a key secondary injury after TBI.
  • Nuclear receptor subfamily 1, group D, member 1 (Nr1d1) influences CNS inflammation and glial activation.
  • The specific role of Nr1d1 in TBI-related M1/M2 microglial polarization and neuroinflammation is not well understood.

Purpose of the Study:

  • To investigate the impact of Nr1d1 activation on neuroinflammatory responses during the acute phase of TBI.
  • To explore Nr1d1's potential as a therapeutic target for TBI.

Main Methods:

  • Activation of Nr1d1 using SR9009 (100 mg/kg) via intraperitoneal injection.
  • Assessment of neurological impairment using the modified neurological severity score (mNSS).
  • Evaluation of molecular changes via Western Blotting and qRT-PCR, cerebral edema via brain water content, and tissue damage via H&E staining.

Main Results:

  • Circadian rhythm of Nr1d1 is disrupted in the acute phase of TBI.
  • Nr1d1 activation mitigated nerve dysfunction and aided neurological recovery.
  • Nr1d1 promoted beneficial microglial phenotype transformation and reduced neuronal and synaptic damage.

Conclusions:

  • Nr1d1 activation demonstrates neuroprotective effects in the acute phase of TBI.
  • Nr1d1 plays a crucial role in regulating neuroinflammation and microglial polarization post-TBI.
  • Targeting Nr1d1 offers a promising therapeutic strategy for TBI treatment and neurological deficit improvement.